Tarpeyo
Named-patient access overview. Tarpeyo is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Tarpeyo (budesonide delayed-release) is a targeted-release oral corticosteroid developed by Calliditas Therapeutics, formulated to deliver budesonide to the distal ileum where IgA-producing immune cells originate. The US Food and Drug Administration granted accelerated approval in December 2021 and converted to full approval in December 2023 for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression, generally defined as a urine protein-to-creatinine ratio of 1.5 g/g or higher. Tarpeyo is given orally as 16 mg once daily, taken in the morning at least one hour before a meal, for a nine-month treatment course, followed by a taper to 8 mg once daily for the final two weeks. The medicine is prescribed and monitored by nephrology in an outpatient setting with attention to standard corticosteroid-class precautions.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tarpeyo
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Tarpeyo is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Tarpeyo in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Tarpeyo
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Tarpeyo if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Tarpeyo for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Tarpeyo through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Tarpeyo. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Tarpeyo through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Tarpeyo to a patient?
Reserve Meds sources Tarpeyo from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Tarpeyo cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Tarpeyo?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.